EMEA Recommends Approval For Astellas’ Mycamine
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21
You may also be interested in...
Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
TOKYO - Astellas posted May 13 fiscal 2007 net revenue of ¥177.4 billion ($1.7 billion), a 32 percent increase over the ¥131.3 billion ($1.3 billion) posted the previous fiscal year. For the present fiscal year however, the Tokyo-based company, which focuses in urology, immunology and inflammatory, diabetes, CNS/pain, infectious diseases and cancer, forecasts a 10.4 percent drop in net revenue to ¥159 billion ($1.518 billion). In a May 14 earnings call with investors and analysts, company president and CEO Masafumi Nogimori noted sales of immunosuppressant Prograf (tacrolimus) grew in each region, with global sales of ¥203 billion. However, the drug's substance patent expired in April. "Based on this, U.S. sales will decline by 5.5 percent," Nogimori said
Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
TOKYO - Astellas posted May 13 fiscal 2007 net revenue of ¥177.4 billion ($1.7 billion), a 32 percent increase over the ¥131.3 billion ($1.3 billion) posted the previous fiscal year. For the present fiscal year however, the Tokyo-based company, which focuses in urology, immunology and inflammatory, diabetes, CNS/pain, infectious diseases and cancer, forecasts a 10.4 percent drop in net revenue to ¥159 billion ($1.518 billion). In a May 14 earnings call with investors and analysts, company president and CEO Masafumi Nogimori noted sales of immunosuppressant Prograf (tacrolimus) grew in each region, with global sales of ¥203 billion. However, the drug's substance patent expired in April. "Based on this, U.S. sales will decline by 5.5 percent," Nogimori said
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo